Virtus ETF Advisers LLC Sells 2,206 Shares of Aimmune Therapeutics Inc (AIMT)

Virtus ETF Advisers LLC lessened its stake in shares of Aimmune Therapeutics Inc (NASDAQ:AIMT) by 13.9% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 13,687 shares of the biotechnology company’s stock after selling 2,206 shares during the period. Virtus ETF Advisers LLC’s holdings in Aimmune Therapeutics were worth $327,000 at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in the stock. BlackRock Inc. raised its holdings in Aimmune Therapeutics by 9.3% during the 3rd quarter. BlackRock Inc. now owns 3,982,580 shares of the biotechnology company’s stock valued at $108,644,000 after buying an additional 338,740 shares during the period. Vanguard Group Inc raised its holdings in Aimmune Therapeutics by 3.9% during the 3rd quarter. Vanguard Group Inc now owns 3,579,306 shares of the biotechnology company’s stock valued at $97,643,000 after buying an additional 135,159 shares during the period. Vanguard Group Inc. raised its holdings in Aimmune Therapeutics by 3.9% during the 3rd quarter. Vanguard Group Inc. now owns 3,579,306 shares of the biotechnology company’s stock valued at $97,643,000 after buying an additional 135,159 shares during the period. Alliancebernstein L.P. raised its holdings in Aimmune Therapeutics by 25.7% during the 3rd quarter. Alliancebernstein L.P. now owns 1,915,689 shares of the biotechnology company’s stock valued at $52,260,000 after buying an additional 391,818 shares during the period. Finally, Emerald Advisers LLC raised its holdings in Aimmune Therapeutics by 52.4% during the 4th quarter. Emerald Advisers LLC now owns 741,746 shares of the biotechnology company’s stock valued at $17,743,000 after buying an additional 255,080 shares during the period. Institutional investors own 76.17% of the company’s stock.

In other Aimmune Therapeutics news, insider Jayson Donald Alexander Dallas bought 3,650 shares of Aimmune Therapeutics stock in a transaction on Monday, November 19th. The shares were acquired at an average price of $27.56 per share, for a total transaction of $100,594.00. Following the completion of the purchase, the insider now directly owns 63,600 shares in the company, valued at approximately $1,752,816. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 14.70% of the company’s stock.

AIMT stock traded down $0.76 during midday trading on Wednesday, reaching $24.02. The company’s stock had a trading volume of 2,105 shares, compared to its average volume of 635,024. Aimmune Therapeutics Inc has a 1 year low of $21.22 and a 1 year high of $42.00. The firm has a market cap of $1.41 billion, a price-to-earnings ratio of -9.23 and a beta of -0.12.

Several analysts recently weighed in on the company. ValuEngine upgraded Aimmune Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday, November 1st. Stifel Nicolaus set a $33.00 price target on Aimmune Therapeutics and gave the company a “hold” rating in a report on Sunday, November 11th. Roth Capital set a $80.00 price target on Aimmune Therapeutics and gave the company a “buy” rating in a report on Sunday, November 11th. Credit Suisse Group set a $40.00 target price on Aimmune Therapeutics and gave the stock a “buy” rating in a research note on Friday, November 9th. Finally, Wedbush assumed coverage on Aimmune Therapeutics in a research note on Wednesday, October 17th. They issued a “buy” rating and a $72.00 target price on the stock. One analyst has rated the stock with a sell rating, four have given a hold rating and seven have assigned a buy rating to the company’s stock. Aimmune Therapeutics has an average rating of “Buy” and a consensus price target of $48.90.

ILLEGAL ACTIVITY NOTICE: This piece was originally posted by Community Financial News and is owned by of Community Financial News. If you are reading this piece on another publication, it was copied illegally and republished in violation of US & international copyright and trademark laws. The legal version of this piece can be read at https://www.com-unik.info/2019/02/13/virtus-etf-advisers-llc-sells-2206-shares-of-aimmune-therapeutics-inc-aimt.html.

Aimmune Therapeutics Profile

Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy product candidate is AR101, an investigational biologic for the treatment of patients with peanut allergy.

Further Reading: Does the Step Transaction Doctrine Affect a Backdoor Roth IRA?

Want to see what other hedge funds are holding AIMT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aimmune Therapeutics Inc (NASDAQ:AIMT).

Institutional Ownership by Quarter for Aimmune Therapeutics (NASDAQ:AIMT)

Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit